First-line Therapy for Renal Cell Carcinoma: Defining New Standards of Care from Phase III Trials


As part of ESMO's continuous commitment to offering beneficial educational material relevant to your work and practice in order to receive your certificate, please complete the Evaluation Survey, which will take approximately 5 minutes. Please indicate which rating reflects your answer.

Questions marked with are required.

1. Do you feel that this E-Learning module provided you with an essential update on targeted agents available for the treatment of patients with renal cell carcinoma (1-not at all; 5-absolutely)

2. Did this E-Learning module provide a good summarised data from recent phase III trials and put into clinical perspective how best to incorporate innovative therapeutics into treatment algorithms (1-not at all; 5-absolutely)

3. Did this E-Learning module provide an update on treatment approaches that are currently under investigation in patients with renal cell carcinoma (1-not at all; 5-absolutely)

4. Please, provide your overall rating of the quality of the education offered by this E-Learning module. (1-poor; 5-excellent)

5. How would you rate the interactivity level offered in the E-Learning material? (1-poor; 5-excellent)

6. Was the information useful and relevant to your work and practice? (1-not at all; 5-absolutely)

7. Do you feel that the information presented was well balanced and supported by adequate evidence? (1-not at all; 5-absolutely)

8. If you would like to add your personal comments or make suggestion to improve future ESMO E-Learning material, please write in the box below: